From lab to venture
Does this discovery have the architecture of an investable asset? Start here before the business plan.
Explore Lab to Venture →Architecting biotech ventures
from lab to deal.
Building equity stories. Securing capital. Driving pharma deals.
Strategic advisory for biotech founders and investors.
VENTURE BUILDING
From discovery to deal. Find where you are.
Most scientific discoveries never become companies. Most companies never close a round. Most assets never reach a pharma deal. The gap is always the same: the wrong architecture underneath the story.
Each stage builds the next — but you can enter at any point.
From venture to investable asset
Build the equity story and milestone map before the first investor meeting.
Explore Investable Asset →From story to capital
Pitch deck audit, VC preparation, EIC Accelerator positioning. Close the gap between a good company and a funded one.
Explore Fundraising →From asset to pharma deal
Strategic business development for licensing or exit. I bridge the gap between clinical milestones and pharmaceutical boardrooms to secure high-value transactions.
Explore Pharma Deal →Italy Gateway
Italy is not a secondary market. It is the entry point.
Italy's IRCCS network offers a distinctive institutional model: over 50 research hospitals where clinical care and scientific research operate under the same roof, in the disease areas where diagnostics innovation matters most. Structuring the right partnerships within this network is the strategic groundwork that determines whether your European market entry starts strong or stalls. The complexity is real. So is the opportunity.
See the Italy Gateway →Clinical evidence strategy
Italy's IRCCS research hospitals combine clinical care with mandated scientific research. Mapping the right institutional partners, the right disease focus, and the right study design is the strategic work that comes before the regulatory execution.
IRCCS network and clinical partnerships
Not all of the over 50 IRCCS are equivalent. Identifying the institutions with the right research infrastructure, the right investigators, and the right disease focus for your product is a strategic decision that shapes everything downstream.
Market entry architecture
Regulatory pathway, clinical partnerships, regional dynamics, procurement logic: an Italian market entry has moving parts that must be assembled in the right sequence. The strategic architecture comes first. The specialist execution follows.
Leonardo Biondi
Biotech Venture Architect · Lecturer, Università Vita-Salute San Raffaele
20 years at the intersection of science, capital, and cross-border deals. I am not a scientist. That is why I ask the questions that matter.
InsightsAll articles
Worth reading. Worth keeping.
Strategic notes on biotech fundraising and venture design. When there is something worth saying. No filler, no cadence for its own sake. Unsubscribe anytime.
No spam. No cadence for its own sake.
In their words
Heard in the room.
“Bridges scientific research and practical applications. Helped establish joint labs across Asia — including labs at NCBS/inStem — a strong model for international collaboration.”
K. VijayRaghavan
Professor Emeritus, NCBS; former Principal Scientific Adviser to the Government of India.
“Very competent in collaboration agreements and negotiations… created a strong bridge between researchers in Japan and Italy.”
Piero Carninci
Head, Genomics Research Center, Human Technopole; President, HUGO (2025–2027).
“A fantastic team player and natural leader who bridges science and business in pharma/biotech.”
Francesco Grillo
Start-up & Portfolio Manager, Max Planck Innovation.
“An exceptionally capable and analytical manager with a deep understanding of the biotech and venture capital industry.”
Jacopo Franchini
Strategic Marketing Advisor, Recordati Rare Diseases.
The gap between your science and its market will not close itself.
30 minutes. No pitch. An honest conversation about where you are and what the next move is.